S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Southwest Oncology Group
• Collaborators: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
• Treatments: Hydroxyurea

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed unresectable primary, recurrent, or residual benign meningioma

• Measurable disease by CT scan or MRI

• Must have disease progression within the past 10 years OR progressive neurologic deficit within the past 6 months

• Must have undergone prior radiotherapy with subsequent disease progression OR refused radiotherapy

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• SWOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• WBC at least 4,000/mm^3

• Platelet count at least lower limit of normal

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No other malignancy within the past 5 years except adequately treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior cytotoxic chemotherapy for meningioma

• Prior mifepristone allowed

• No other concurrent chemotherapy

Endocrine therapy:

• Concurrent glucocorticoids and hormone replacement therapy allowed if stable dose maintained for at least 72 hours prior to CT scan or MRI

• No concurrent antitumor hormonal therapy

Radiotherapy:

• See Disease Characteristics

• At least 6 months since prior radiotherapy

• No concurrent radiotherapy

Surgery:

• Not specified